EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease

Viswanath Devanarayan iD, Michael C Donohue, Reisa A Sperling, Keith A Johnson, Yuanqing Ye, Arnaud Charil, Thomas Doherty, Lu Tian, Rema Raman, Paul S Aisen, Lynn D Kramer, Michael C Irizarry und 1 weitere

Alzheimer's & Dementia · 2025-09 · 21 (9)

DOI: 10.1002/alz.70702 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Alzheimer's & Dementia, online erschienen am 24.09.2025. Verfasst von Viswanath Devanarayan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research, Eisai Inc, Nutley, New Jersey, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NIH HHS, Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Cognitive decline in asymptomatic preclinical Alzheimer's disease (AD) is slow and variable, limiting detection of treatment effects. This study developed models to forecast trajectories and improve trial efficiency. METHODS Models were trained on longitudinal Preclinical Alzheimer's Cognitive Composite (PACC) data up to 240 weeks from the Phase III A4 study of solanezumab. Baseline inputs included demographics, apolipoprotein E ( APOE ) ε4, clinical scores, amyloid positron emission tomography (PET), plasma pTau217, magnetic resonance imaging (MRI), and tau PET (sub‐study). Stochastic gradient boosting was used, with evaluation via cross‐validation and trial simulations. RESULTS The best model without tau PET used pTau217, clinical, and MRI data ( R 2 = 0.32; area under the receiver operating characteristic curve (AUROC) for classifying a 0.5‐point PACC decline = 78.6%). Replacing MRI with tau PET improved performance ( R 2 = 0.42; AUROC = 83.1%). Predicted trajectories as a prognostic covariate reduced sample sizes by 35% and increased power from 80% to 94.7%. DISCUSSION Prognostic models can predict decline in preclinical AD and improve trial efficiency. CLINICALTRIALS.GOV IDENTIFIERS NCT02008357 (Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)) Highlights Models forecast 4.5‐year cognitive decline in amyloid‐positive preclinical Alzheimer's disease (AD). Plasma pTau217 and tau positron emission tomography (PET) standardized uptake value ratios (SUVRs) in early‐accumulating regions are key predictors. Tau PET improves prediction beyond plasma, magnetic resonance imaging (MRI), and clinical measures. Forecasted decline as a prognostic covariate improves power and cuts sample size in trial simulations. Alternative models underperform yet retain practical utility when tau PET or pTau217 is unavailable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionAgedFemaleHumansMaleAntibodies, Monoclonal, HumanizedBrainLongitudinal StudiesMagnetic Resonance ImagingPositron-Emission TomographyPrognosistau Proteins

Stichwörter der Autor:innen

MRIPACCblood‐based biomarkersdisease progressionimagingmachine learningpredictionprognostic covariatetau PET

Substanzen

Antibodies, Monoclonal, Humanizedsolanezumabtau Proteins

Autor:innen und Institutionen

  • Clinical Research, Eisai Inc, Nutley, New Jersey, USA.
  • Department of Mathematics, Statistics, and Computer Science, University of Illinois Chicago, Chicago, Illinois, USA.
  • Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, California, USA.
  • Center for Alzheimer's Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Departments of Radiology and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Clinical Research, Eisai Ltd., Hatfield, UK.

ORCID-Profile: Viswanath Devanarayan

Förderung

  • NIA NIH HHS
  • NIH HHS
  • Eli Lilly and Company
  • Alzheimer's Association
  • Accelerating Medicines Partnership
  • GHR Foundation
  • Eisai Inc.
  • National Institute on Aging

Zitieren

APA

Devanarayan, V., Donohue, M. C., Sperling, R. A., Johnson, K. A., Ye, Y., Charil, A., Doherty, T., Tian, L., Raman, R., Aisen, P. S., Kramer, L. D., Irizarry, M. C., & Dhadda, S. (2025). Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease. Alzheimer's & Dementia, 21(9). https://doi.org/10.1002/alz.70702

Vancouver

Devanarayan V, Donohue MC, Sperling RA, Johnson KA, Ye Y, Charil A, et al. Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease. Alzheimer's & Dementia. 2025;21(9). doi:10.1002/alz.70702

BibTeX
@article{Devanarayan2025,
  author = {Devanarayan, Viswanath and Donohue, Michael C and Sperling, Reisa A and Johnson, Keith A and Ye, Yuanqing and Charil, Arnaud and Doherty, Thomas and Tian, Lu and Raman, Rema and Aisen, Paul S and Kramer, Lynn D and Irizarry, Michael C and Dhadda, Shobha},
  title = {Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {9},
  doi = {10.1002/alz.70702}
}
Kostenlos starten →